Skip to main content

Advertisement

Table 3 CellTiter-Glo® and microscopic evaluation of a small subset (n = 25) of an FDA-approved compound library. Values of % reduced viability of compound-treated NTS relative to the controls were based on average luminescence for CellTiter-Glo® (subtracted from background) and on average viability scores for the microscopic evaluation.

From: Fluorescence/luminescence-based markers for the assessment of Schistosoma mansoni schistosomula drug assays

  % reduced viability relative to controls
Compound CellTiter-Glo® Microscopic Evaluation
acemetacin 0 11.1
benzalkonium chloride 94.9 100
cefpodoxime proxetil 0 0
clofazimine 85.2 100
clofibric acid 0 0
docosanol 0 0
docusate sodium 0 0
ecamsule triethanolamine 0 0
eletriptan hydrobromide 0 0
etidronate disodium 0 0
flumazenil 0.5 0
lomerazine hydrochloride 78.6 100
methylbenzethonium chloride 84.5 100
nicardipine hydrochloride 76.8 88.9
perhexiline maleate 94.5 100
pipamperone 0 0
pipemidic acid 0 0
quinine ethyl carbonate 0 0
ritodrine hydrochloride 0 0
saccharin 0 0
spiramycin 0 0
sulpiride 0 0
tamoxifen citrate 85.4 100
teicoplanin 0 0
tetramizole hydrochloride 0 0